943247-31-2

Upstream product

• 85-44-9 phthalic anhydride 
• 2250-53-5 3-amino-5-(trifluoromethyl)-1H-indazole 

Downstream Products

• 1338358-50-1 2-(1-benzyl-5-trifluoromethyl-1H-indazol-3-yl)-isoindole-1,3-dione 
• 1338357-85-9 N-azetidin-3-yl-2-(1-benzyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide 
• 1338358-07-8 C₁₇H₁₄F₃N₃O₂ 

Relevant academic research and scientific papers

Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists

A novel series of 4-azetidinyl-1-aryl-cyclohexanes containing indazole or benzoisoxazole moiety have been identified as potent CCR2 antagonists with high selectivity versus hERG.

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

GLUCOKINASE ACTIVATORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of wherein the variables are as defined herein.